Since its inception in 2012, CanXida Remove has been a cornerstone in our mission to support gut health and combat fungal overgrowth. To further validate the efficacy of our formula, we conducted an extensive review of the scientific literature, encompassing in vitro, in vivo, and clinical studies, to evaluate the effectiveness of our key ingredients against various Candida species.
To present this data clearly, we have organized the ingredients alphabetically for ease of reference:
- A. Garlic 2% (Allicin)
- B. Caprylic Acid
- C. Undecylenic Acid
- D. Betaine HCL
- E. Grapefruit Seed Extract 45% Flavonoid
- F. Black Walnut Hull Extract
- G. Pau D’arco 4:1 Extract
- H. Neem 4:1 Extract
- I. Berberine HCL (Berberine Concentrate HCl 85%)
- J. Clove 4:1 Extract
- K. Biotin
- L. Oregano Oil
The table below presents a comprehensive analysis of this research, highlighting the ingredient names, the type of study conducted, the specific Candida species targeted, the findings, the efficacy levels, and the corresponding citations.
This detailed review not only underscores the potency of CanXida Remove but also provides a transparent view of the scientific validation supporting its use. Discover how each ingredient contributes to the overall effectiveness of CanXida Remove in managing and mitigating Candida overgrowth and promoting a healthier gut.
| Antifungal Potential of ingredients A-L | ||||||
| Ingredient | Study type | Target species | Findings | Efficacy | Citation | |
| A | Clinical | Candida spp. | Women with colony count of candida > 100 cfu/ml were 73% as compared to placebo with 93% | Low | Watson et al., 2014 | |
| A | Clinical | Candida spp | Application of 5gram garlic gel/day reduced candidal vaginitis infection from 100% to 2.6% after 30 days as compared to clotrimazole (2%) that reduced the infection to 0% | High | Farshbaf et al., 2016 | |
| A | Clinical | Candida spp | 1500 mg/day garlic for 7 days reduced candidal vaginitis related symptoms up to 44% as compared to fluconazole showed 63.5% at 150 mg/day. | Medium | Ebrahimy et al., 2015 | |
| A | In vivo | Candida albicans | garlic extract (0.25 g/ kg b. w) reduced C. albicans concentrations in liver and kidneys homogenates in infected control and diabetic rats | Medium | Bokaeian et al., 2010 | |
| A | In vitro | Candida albicans | ZOI was 32 mm at 200mg/ml | High | Hamzah et al., 2022 | |
| A | In vitro | Candida albicans | ZOI was 13 mm at 1 mg/ml | Medium | Ashrit,, et al., 2022 | |
| A | In vitro | Candida albicans | ZOI was 27 mm at 500 mg/ml of garlic extract as compared to ZOI of 29 mm of ciprofloxacin at 5 µg/ml | Low | Ashrit,, et al., 2022 | |
| A | In vitro | Candida albicans | MIC was 200 mg/mL | Low | Adejare et al., 2013 | |
| A | In vitro | Candida glabrata | MIC was 200 mg/mL | Low | Adejare et al., 2013 | |
| A | In vitro | Candida glabrata | MFC was 3.13 µg/mL | Medium | Chinedu, 2019 | |
| B | In vitro | Candida albicans | MFC was 2 mg/mL | Medium | Jadhav et al., 2017 | |
| B | In vitro | Candida albicans | MIC was 450 µg/mL | Medium | Zarimeidani et al., 2021 | |
| C | In vitro | Candida albicans | 80% reduction in C. albicans biomass production at 5mM | High | Shi et al., 2016 | |
| E | In vitro | Candida albicans | ZOI was 24 mm at 200 μg/ml | High | Han, 2017 | |
| E | In vitro | Candida albicans | ZOI was 8 mm at 20 mg/ml | Low | Shrestha et al., 2012 | |
| E | In vitro | Candida albicans | MIC was 8 mg/mL | Low | Aslanimehr et al., 2020 | |
| E | In vitro | Candida albicans | ZOI was 11 mm at 8.25 (% m/v) | Low | Cvetnic et al., 2004 | |
| E | In vitro | Candida albicans | MBC was 1.2mg/ml | Medium | Aslanimehr et al., 2020 | |
| E | In vitro | Candida krusei | ZOI was 23 mm at 800 μg/ml | Medium | Eslami et al., 2017 | |
| E | In vitro | Candida krusei | ZOI was 12 mm at 8.25 (% m/v) | Low | Cvetnic et al., 2004 | |
| E | In vitro | Candida glabrata | ZOI was 21 mm at 800 μg/ml | Medium | Eslami et al., 2017 | |
| E | In vitro | Candida tropicalis | ZOI was 13 mm at 16.50 (% m/v) | Low | Cvetnic et al., 2004 | |
| E | In vivo | C. albicans | Mice receiving no GSE had the survival time of 11 days against disseminated candidiasis as compared to 24 days wherein mice received 4 mg/kg body weight of GSE | High | Han, 2017 | |
| F | In vivo | C. albicans | The CFUs before intervention was 308.2 and reduced to 0 in both 4% juglone group and 1% clotrimazole | High | Wianowska et al., 2016 | |
| F | In vitro | C. albicans | 100% growth reduction at 337 mg/ml | High | Salamat et al., 2016 | |
| F | In vitro | Candida krusei, | Comparable inhibition to fluconazole | High | Rodrigues, 2010 | |
| I | In vitro | Candida albicans | MICs was 80 μg/mL | High | Xie et al. 2020 | |
| I | In vitro | Candida albicans | MICs of berberine was 8 μg/mL and Fluconazole was 16 μg/mL | High | da Silva et al. 2016 | |
| I | In Vitro | Candida albicans | MIC of fluconazole was 1.9 lg/ml alone and decreased to 0.48 lg/ml in the presence of berberine concentrations of 1.9 lg/ml | High | Iwazaki et al. 2010 | |
| I | In vitro | Candida albicans | MIC values ranging from 125 to 500μg/ml. | Medium | Poopedi et al. 2021 | |
| I | In vitro | Candida albicans | MICs was 31.25 μg/mL alone and combo with Fluconazole was 3.90 μg/mL | Medium | Wei et al,. 2011 | |
| I | In vitro | Candida albicans | Combo of 100 µg berberine and 6 µg terbinafine showed an increased inhibition zones in size (inhibition zone, 25.67±2.52 mm) | High | Lam, et al. 2016 | |
| I | In vitro | Candida krusei | MICs of berberine was 4 μg/mL and Fluconazole was 16 μg/mL | Low | da Silva et al. 2016 | |
| I | In vitro | Candida krusei | MICs was 10 μg/mL | High | Xie et al. 2020 | |
| I | In vitro | Candida tropicalis | MICs of berberine was 8 μg/mL and Fluconazole was 32 μg/mL | High | da Silva et al. 2016 | |
| I | In vitro | Candida tropicali | MIC was 16 µg/mL and 8 µg/mL combo with fluconazole with fractional inhibitory concentration index (FICI) 0.13 | High | Shao, et al. 2016 | |
| I | In vitro | Candida parapsilosis | MICs of berberine was 8 μg/mL and Fluconazole was 32 μg/mL | High | da Silva et al. 2016 | |
| I | In vitro | Candida parapsilosis | MIC was 16 µg/mL and 8 µg/mL combo with fluconazole with fractional inhibitory concentration index (FICI) 0.13 | Medium | Shao, et al. 2016 | |
| I | In vitro | Candida glabrata | MICs was 20 μg/mL | High | Xie et al. 2020 | |
| I | In vitro | Candida dubliniensis | MICs was 40 μg/mL | High | Xie et al. 2020 | |
| I | In vitro | Cryptococcus neoformans | MICs of berberine was 16 μg/mL and Fluconazole was 64 μg/mL | High | da Silva et al. 2016 | |
| I | In vitro | Trichosporon Asahii | MIC was 84.4 µg/mL and 28.9 µg/mL combo with fluconazole with fractional inhibitory concentration index (FICI) 0.65 | Low | Cong, et al. 2017 | |
| H | In vitro | Candida albicans | Didn’t inhibit the growth of any strain in concentrations as from 0.1 g/ml | Low | Polaquini et al. 2006 | |
| H | In vitro | Candida albicans | Zone of inhibition was 5.8 ± 4.26 mm at 5 mg/ml | Medium | Bansal et al. 2019 | |
| H | In vitro | Candida albicans | Zone of inhibition was 41.59 mm at 20μg/ml | High | Singh et al. 2023 | |
| H | In vitro | Candida albicans | MICs was 1.2 mg/mL | High | SaiRam, et al 2000. | |
| H | In vitro | Candida albicans | Inhibition of 21 mm after 24 hours and 18 mm after seven
Days |
High | Barua, el at. 2017 | |
| H | In vivo | Candida albicans | LD50 was (3809.6 mg/kg). | High | Faal, et al. 2012 | |
| H | In vitro | Aspergillus niger | Zone of inhibition was 17.41 mm at 20 mg/ml | Medium | Singh et al. 2023 | |
| J | In vivo | Candida albicans | zone of inhibition (ZOI) was 1.25 ± 0.05 cm at 5.0 mg | Medium | Ahmad, et al.2005 | |
| J | In vivo | Candida albicans | At Day 7: Lesion-free, normal thickness, hair regrowth, and reduced IL-6 levels (5.52 ±1.67) post-treatment. | High | Ali et al. 2023 | |
| J | In vivo | Candida albicans | clove oil gel was found to have the lowest clearance | low | Alkhanjaf et al. 2022 | |
| J | In vivo | Candida albicans | (0.1%, 0.2%) were able to kill 100% cells | High | Chami, et al. 2005 | |
| J | In vitro | Candida sp | 68.4–84.2% of the yeast reduction in biofilm formation, | High | Rajkowska et al. 2019 | |
| J | In vitro | Candida albicans | 0.5-2.0% v/v in Graph of percentage inhibition of diameter growth (PIDG) were -ve, except for 2.5% v/v, which showed 21.43% | High | Latifah-Munirah et al. 2015 | |
| J | In vitro | Candida albicans | MIC was 500 µg/ml | Medium | Shahina, et al. 2022 | |
| J | In vivo | Cryptococcus neoformans | zone of inhibition (ZOI) was 1.35 ± 0.05 cm at 5.0 mg | low | Ahmad, et al.2005 | |
| J | In vivo | Aspergillus. fumigatus | zone of inhibition (ZOI) was 2.0 ± 0.2 cm at 5.0 mg | High | Ahmad, et al.2005 | |
| L | In vivo | Candida albicans | 0.033% stopped the growth
of cells |
High | Chami, et al. 2005 | |
| L | In vivo | Candida albicans | MIC was 0.25 mg/ml | Medium | Manohar, et al. 2001 | |
| L | In vivo | Candida glabrata | Mean inhibition zone was 54.7 ± 2.1 mm | Medium | Fernandes, et al. 2023 | |
| L | In vivo | Candida albicans | Mean inhibition zone was 30.3 ± 2.9 mm | Low | Fernandes, et al. 2023 | |
| L | In vivo | Candida krusei | Mean inhibition zone was 43.7 ± 3.2 mm | Medium | Fernandes, et al. 2023 | |
| L | In vivo | Candida guilliermondii | Mean inhibition zone was 77.3 ± 3.1 mm | High | Fernandes, et al. 2023 | |
| L | In vitro | Candida albicans | MIC was 0.01mg/L | High | Cid-Chevecich, et al. 2022 | |
| L | In vitro | Candida dubliniensis | MIC was 2.6mg/L | Medium | Cid-Chevecich, et al. 2022 | |
| L | In vitro | Candida krusei | MIC was 5.33mg/L | High | Cid-Chevecich, et al. 2022 | |
| L | In vivo | Candida albicans | MIC were 1.2 µl/mL | Medium | Clef et al. 2011 | |
| L | In vivo | Candida albicans | Inhibition zone was 4 to 17 mm | High | Hosny, et al. 2021 | |
Addressing Low Efficacy in In-Vitro Studies
While reviewing the scientific literature for the ingredients in CanXida Remove, you may notice that some in-vitro studies report lower efficacy levels. It’s important to understand the context and limitations of these findings to fully appreciate the overall potency and effectiveness of our product.
1. Context of In-Vitro Studies: In-vitro studies are conducted in a controlled laboratory environment outside of a living organism. These studies are essential for understanding the basic interactions between compounds and microorganisms. However, they do not always replicate the complex biological processes that occur within the human body. An ingredient might show lower efficacy in-vitro but perform significantly better in-vivo or in clinical settings due to factors such as bioavailability, metabolism, and synergistic effects with other ingredients.
2. Synergistic Effects: CanXida Remove is a carefully formulated blend of multiple ingredients, each chosen for their unique properties and potential to work synergistically. While individual components may show varying degrees of efficacy in isolation, their combined effect in a real-world scenario often leads to enhanced overall performance. This synergy can result in a more potent and comprehensive antifungal action against Candida species than any single ingredient could achieve on its own.
3. Varied Strains and Conditions: The efficacy of an ingredient can also vary depending on the specific strain of Candida and the conditions under which the study was conducted. Some strains may be more resistant or sensitive to certain compounds. The low efficacy observed in some studies might be strain-specific and not necessarily indicative of the ingredient’s performance against other strains or in different conditions.
4. Holistic Approach to Gut Health: CanXida Remove is designed to support gut health holistically. Beyond its antifungal properties, the formulation includes ingredients that support digestive health, immune function, and overall well-being. This multi-faceted approach ensures that users not only combat fungal overgrowth but also address other underlying issues contributing to gut health problems.
5. In-Vitro Testing as a First Step: We have also tested CanXida Remove in-vitro/lab settings as a crucial first step to understand how our product works. These preliminary tests provide valuable insights and guide further research. To build on this foundation, CanXida Remove is currently undergoing clinical trial. This virtual, double-blind, two-arm, randomized, placebo-controlled clinical trial will last 12 weeks. Participants will take the CanXida Remove or a placebo product daily and complete questionnaires at Baseline, Week 6, and Week 12.
At CanXida, our goal is to share as much information as possible, not just with our customers but also with the clinicians who use our products worldwide. By publishing extensive articles and sharing detailed technical information, we aim to provide a transparent and comprehensive understanding of the efficacy and benefits of our formulations. This commitment to transparency and education helps ensure that everyone, from consumers to healthcare professionals, can make informed decisions about their health and the products they use.
By considering the broader context and the comprehensive design of CanXida Remove, you can see that the occasional low efficacy in in-vitro studies does not undermine the overall potency and effectiveness of CanXida Remove. The combined strength of our ingredients, backed by extensive research and real-world results, ensures that CanXida Remove remains a highly effective solution for managing Candida overgrowth and promoting optimal gut health.